FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2909699833> ?p ?o ?g. }

• W2909699833 endingPage "62" @default.
• W2909699833 startingPage "49" @default.
• W2909699833 abstract "Telomerase-mediated immortalization and proliferation of tumor cells is a promising anti-cancer treatment strategy and development of potent telomerase inhibitors is believed to open new window of treatments in human malignancies. In the present study, we found that BIBR1532, a small molecule inhibitor of human telomerase, exerted cytotoxic effects on a panel of human cancer cells spanning from solid tumors to hematologic malignancies; however, as compared with solid tumors, leukemic cells were more sensitive to this inhibitor. This was independent of molecular status of p53 in the leukemic cells. The results of a miRNA PCR array revealed that BIBR1532-induced cytotoxic effects in NB4, the most sensitive cell line, was coupled with alteration in a substantial number of cancer-related miRNAs. Interestingly, most of these miRNAs were found to act as tumor suppressors with validated targets in cell cycle or nuclear factor (NF)-κB–mediated apoptosis. In accordance with a bioinformatics analysis, our experimental studies showed that BIBR1532-induced apoptosis is mediated, at least partly, by inhibition of NF-κB. Moreover, we found that the alteration in the expression of miRNAs was coupled with the alteration in the cell cycle progression. To sum up with, a straightforward interpretation of our results is that telomerase inhibition using BIBR1532 not only induced CDKN1A-mediated G1 arrest in NB4, but also resulted in a caspase-3-dependent apoptotic cell death mostly through suppression of NF-κB axis." @default.
• W2909699833 created "2019-01-25" @default.
• W2909699833 creator A5024170843 @default.
• W2909699833 creator A5036464666 @default.
• W2909699833 creator A5036536670 @default.
• W2909699833 creator A5066883249 @default.
• W2909699833 creator A5072758074 @default.
• W2909699833 creator A5076707279 @default.
• W2909699833 creator A5090828119 @default.
• W2909699833 date "2019-03-01" @default.
• W2909699833 modified "2023-10-17" @default.
• W2909699833 title "Contributory role of microRNAs in anti-cancer effects of small molecule inhibitor of telomerase (BIBR1532) on acute promyelocytic leukemia cell line" @default.
• W2909699833 cites W1595724240 @default.
• W2909699833 cites W1920354401 @default.
• W2909699833 cites W1958510895 @default.
• W2909699833 cites W1969903944 @default.
• W2909699833 cites W1970712795 @default.
• W2909699833 cites W1972071205 @default.
• W2909699833 cites W1972371148 @default.
• W2909699833 cites W1972380031 @default.
• W2909699833 cites W1975547412 @default.
• W2909699833 cites W1985997519 @default.
• W2909699833 cites W1987930421 @default.
• W2909699833 cites W1989328481 @default.
• W2909699833 cites W1993916353 @default.
• W2909699833 cites W2002995168 @default.
• W2909699833 cites W2003474867 @default.
• W2909699833 cites W2004462371 @default.
• W2909699833 cites W2009186918 @default.
• W2909699833 cites W2015352009 @default.
• W2909699833 cites W2022753987 @default.
• W2909699833 cites W2023394407 @default.
• W2909699833 cites W2025535465 @default.
• W2909699833 cites W2030166934 @default.
• W2909699833 cites W2036854871 @default.
• W2909699833 cites W2038684002 @default.
• W2909699833 cites W2042907812 @default.
• W2909699833 cites W2045881743 @default.
• W2909699833 cites W2053863057 @default.
• W2909699833 cites W2057730598 @default.
• W2909699833 cites W2060347289 @default.
• W2909699833 cites W2067250022 @default.
• W2909699833 cites W2073887986 @default.
• W2909699833 cites W2083010694 @default.
• W2909699833 cites W2089277080 @default.
• W2909699833 cites W2090844380 @default.
• W2909699833 cites W2092476508 @default.
• W2909699833 cites W2096203569 @default.
• W2909699833 cites W2102073127 @default.
• W2909699833 cites W2106958499 @default.
• W2909699833 cites W2111471857 @default.
• W2909699833 cites W2123731469 @default.
• W2909699833 cites W2125536613 @default.
• W2909699833 cites W2126850174 @default.
• W2909699833 cites W2127300984 @default.
• W2909699833 cites W2137876309 @default.
• W2909699833 cites W2145028653 @default.
• W2909699833 cites W2145344158 @default.
• W2909699833 cites W2149954427 @default.
• W2909699833 cites W2153381693 @default.
• W2909699833 cites W2154040159 @default.
• W2909699833 cites W2154116432 @default.
• W2909699833 cites W2154872048 @default.
• W2909699833 cites W2164487353 @default.
• W2909699833 cites W2171178873 @default.
• W2909699833 cites W2181143085 @default.
• W2909699833 cites W2217346917 @default.
• W2909699833 cites W2264852674 @default.
• W2909699833 cites W2395740875 @default.
• W2909699833 cites W2431989793 @default.
• W2909699833 cites W2514536348 @default.
• W2909699833 cites W2530469682 @default.
• W2909699833 cites W2532189621 @default.
• W2909699833 cites W2547211258 @default.
• W2909699833 cites W2563387326 @default.
• W2909699833 cites W2570262869 @default.
• W2909699833 cites W2598763231 @default.
• W2909699833 cites W2615838222 @default.
• W2909699833 cites W2662520946 @default.
• W2909699833 cites W2744892547 @default.
• W2909699833 cites W2745415184 @default.
• W2909699833 cites W2761690600 @default.
• W2909699833 cites W2766653678 @default.
• W2909699833 cites W2767676602 @default.
• W2909699833 cites W2770441238 @default.
• W2909699833 cites W2797271813 @default.
• W2909699833 doi "https://doi.org/10.1016/j.ejphar.2019.01.018" @default.
• W2909699833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30658112" @default.
• W2909699833 hasPublicationYear "2019" @default.
• W2909699833 type Work @default.
• W2909699833 sameAs 2909699833 @default.
• W2909699833 citedByCount "18" @default.
• W2909699833 countsByYear W29096998332019 @default.
• W2909699833 countsByYear W29096998332020 @default.
• W2909699833 countsByYear W29096998332021 @default.
• W2909699833 countsByYear W29096998332022 @default.
• W2909699833 countsByYear W29096998332023 @default.
• W2909699833 crossrefType "journal-article" @default.

• next